Table 1.
Baseline characteristics of the subjects
| Characteristics | Light | Dark | ||
|---|---|---|---|---|
| OLED | eInk | OLED | eInk | |
| Number of subjects | 29 | 31 | 31 | 28 |
| Age, years (range) | 24 (23–25) | 24 (23–25) | 25 (23–26.5) | 24 (23–27) |
| Sex, male/female | 9/20 | 8/23 | 11/20 | 13/15 |
| NIBUT‐First, s | 6.64 (5.35–8.20) | 6.22 (4.64–8.91) | 6.49 (5.58–8.1) | 6.79 (5.13–8.07) |
| NIBUT‐Average,s | 7.77 (6.95–9.35) | 8.28 (6.44–9.67) | 8.25 (7.35–9.30) | 7.80 (6.71–8.92) |
| FBUT‐Average, s | 4.40 (2.98–7.39) | 3.93 (2.19–5.78) | 4.83 (3.14–6.84) | 4.05 (3.51–7.94) |
| NIKTMH, mm | 0.19 (0.15–0.23) | 0.19 (0.15–0.22) | 0.17 (0.15–0.21) | 0.17 (0.15–0.21) |
| Schirmer I test, mm | 11.00 (7.50–18.00) | 14.00 (10.00–21.80) | 11.00 (5.00–19.30) | 15.00(8.00–27.00) |
| Nasal redness, 0–4 | 0.75 (0.60–1.00) | 0.80 (0.60–1.08) | 0.80 (0.60–0.90) | 0.85 (0.78–1.03) |
| Temporal redness, 0–4 | 0.75 (0.60–1.00) | 0.80 (0.60–1.10) | 0.80 (0.70–1.00) | 0.90 (0.70–1.00) |
| CFS score, 0–15 | 0.00 (0.00–1.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) |
| MG expressibility, 0–9 | 1.00 (0.00–1.00) | 1.00 (0.00–2.00) | 1.00 (0.00–2.00) | 1.00 (0.00–3.00) |
| MG quality, 0–45 | 1.00 (0.00–6.00) | 5.00 (0.00–11.00) | 3.00 (1.00–9.00) | 4.00 (0.00–11.00) |
| OSDI total, 0–100 | 17.92 (10.42–22.92) | 11.83 (9.75–20.17) | 14.58 (6.25–23.96) | 16.29 (10.81–24.10) |
| CVS‐Q total, 0–138 | 14.00 (7.00–24.00) | 14.00 (8.50–18.50) | 15.00 (11.00–23.00) | 14.00 (5.75–18.75) |
| BCVA RE | 1.00 (0.80–1.20) | 1.00 (0.80–1.20) | 1.00 (0.80–1.00) | 1.00 (0.80–1.20) |
| BCVA LE | 1.00 (0.80–1.20) | 1.00 (0.80–1.20) | 1.00 (0.80–1.10) | 1.00 (0.80–1.20) |
| IOP, mmHg | 12.3 (11.3–13.35) | 12.4 (11.2–14.00) | 13.5 (11.3–16.05) | 12.3 (11.05–15.6) |
Dates are presented as median and interquartile ranges.
BCVA, best corrected visual acuity; CFS, corneal fluorescein staining; CVS‐Q, computer vision syndrome questionnaire; eInk, electronic ink; FBUT, fluorescein break‐up time; IOP, intraocular pressure; LE, left eye; MG, meibomian gland; NIBUT, noninvasive break‐up time; NIKTMH, noninvasive keratograph tear meniscus height; OLED, organic light‐emitting diode; OSDI, ocular surface disease index; RE, right eye.